MedDataX Logo

Atrophic Gastritis Predicts the Risk of Gastric Cancer

NCT ID: NCT06203327

Last Updated: 2024-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2042 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-15

Study Completion Date

2034-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrophic Gastritis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Atrophic Gastritis Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OLGA 0-I

Esophagogastroscopy (OLGA 0-Ⅰ)

Intervention Type OTHER

Surveillance endoscopies at years 3-5.

OLGA II

Esophagogastroscopy (OLGA II)

Intervention Type OTHER

Surveillance endoscopies at years 2-3.

OLGA III-IV

Esophagogastroscopy (OLGA III-IV)

Intervention Type OTHER

Surveillance endoscopies every year.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esophagogastroscopy (OLGA 0-Ⅰ)

Surveillance endoscopies at years 3-5.

Intervention Type OTHER

Esophagogastroscopy (OLGA II)

Surveillance endoscopies at years 2-3.

Intervention Type OTHER

Esophagogastroscopy (OLGA III-IV)

Surveillance endoscopies every year.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability and willingness to participate in the study and to sign and give informed consent
* Biopsies were collected based on the recommendation of updated Sydney system

Exclusion Criteria

* under 18 or over 80 years old
* history of gastrectomy
* severe systemic diseases or malignancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hong Lu, MD

Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yu Huang, M.M.

Role: primary

Hong Lu, M.D.,Ph.D

Role: backup

Jinnan Chen, M.M.

Role: backup

Yixian Guo, M.M.

Role: backup

Xiao Liang, M.D.,Ph.D

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

rjhy20230004

Identifier Type: -

Identifier Source: org_study_id